# Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

> **NCT00479219** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 17 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** GSI-953
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00479219
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2008-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479219, "Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00479219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*